MT Newswires
Gilead Says Single Tablet of Bictegravir, Lenacapavir to Treat HIV Meets Primary Goal in Phase 3 Trial
➖
AI Sentiment
Neutral
5/10
Gilead Sciences Inc. News
Latest updates and market news for GILD
12 news
Dec 11 - Dec 17, 2025
Page 1
Business Wire
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)?
📈
AI Sentiment
Highly Positive
8/10
Investor's Business Daily
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak
⚠️
AI Sentiment
Highly Negative
1/10
Zacks
Kymera's Eczema Drug Gets Fast Track Designation in the United States
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating
📊
AI Sentiment
Positive
6/10
MT Newswires
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall
➖
AI Sentiment
Neutral
4/10
BioPharma Dive
Arcus cancels work on Gilead-partnered cancer combo after trial setback
📉
AI Sentiment
Negative
2/10
PR Newswire
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
📈
AI Sentiment
Highly Positive
9/10
Insider Monkey
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment
📈
AI Sentiment
Highly Positive
8/10
Share this news page